Literature DB >> 1336626

Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis.

F T Vertosick1, R G Selker.   

Abstract

Long-term survival after the diagnosis of malignant glioma is uncommon but not rare. To define better the population of patients who have extended survival with this disease, we reviewed the records of 22 of our patients who survived more than 4 years after the biopsy-proven diagnosis of anaplastic astrocytoma, malignant mixed glioma, or glioblastoma multiforme. Surprisingly, 21 of the 22 patients are still alive and being actively followed by the authors. The long-term survivors were typically young and with minimal or no functional impairment at the time of diagnosis. Survivals ranged from 4.2 to 15.8 years. The quality of survival was generally good, with the surviving patients having a mean Karnofsky Performance Score of 76. Three-quarters of the patients had no enhancement or mass effect on their most recent computed tomography scans. A review of the available literature, together with our own series, suggests that death from recurrent disease is unusual in glioma patients who survive more than 4 or 5 years.

Entities:  

Mesh:

Year:  1992        PMID: 1336626     DOI: 10.1016/0090-3019(92)90022-f

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  11 in total

1.  Long-term survival in a patient with supratentorial glioblastoma: clinical considerations.

Authors:  L Cervoni; P Celli; M Salvati
Journal:  Ital J Neurol Sci       Date:  1998-08

2.  TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.

Authors:  J A Kraus; M Wenghoefer; N Glesmann; S Mohr; M Beck; M C Schmidt; R Schröder; U Berweiler; W Roggendorf; S Diete; K Dietzmann; K Heuser; B Müller; R Fimmers; A von Deimling; U Schlegel
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

3.  Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.

Authors:  J A Kraus; N Glesmann; M Beck; D Krex; T Klockgether; G Schackert; U Schlegel
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

Review 4.  Long-term survival in patients with supratentorial glioblastoma.

Authors:  M Salvati; L Cervoni; M Artico; R Caruso; F M Gagliardi
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

5.  Exophytic malignant brainstem mixed glioma in an adult: a case report.

Authors:  T T Lee; M Galarza; C K Petito; R C Heros
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

6.  Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.

Authors:  M Morita; M K Rosenblum; M H Bilsky; R A Fraser; M R Rosenfeld
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

7.  Immunohistochemical markers for prognosis of cerebral glioblastomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

8.  Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience.

Authors:  Martina Baur; Matthias Preusser; Maria Piribauer; Katarzyna Elandt; Marco Hassler; Marcus Hudec; Christian Dittrich; Christine Marosi
Journal:  Radiol Oncol       Date:  2010-05-24       Impact factor: 2.991

9.  Clinicopathological features and molecular analysis of primary glioblastomas in Moroccan patients.

Authors:  Said Hilmani; Omar Abidi; Houda Benrahma; Mehdi Karkouri; Souha Sahraoui; Abdessamad El Azhari; Abdelhamid Barakat
Journal:  J Mol Neurosci       Date:  2012-08-04       Impact factor: 2.866

10.  IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.

Authors:  Aymeric Amelot; Patricia De Cremoux; Véronique Quillien; Marc Polivka; Homa Adle-Biassette; Jacqueline Lehmann-Che; Laurence Françoise; Antoine F Carpentier; Bernard George; Emmanuel Mandonnet; Sébastien Froelich
Journal:  PLoS One       Date:  2015-07-09       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.